P27 Kip1 in stage III colon cancer: Implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 2116-2122

  Bertagnolli, Monica M ^a,b   S Warren, Robert ^c   Niedzwiecki, Donna ^d   Mueller, Elke ^a   Compton, Carolyn C ^e   Redston, Mark ^a   Hall, Margaret ^d   Hahn, Hejin P ^a   Jewell, Scott D ^f   Mayer, Robert J ^b   Goldberg, Richard M ^g   Saltz, Leonard B ^h   Loda, Massimo ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; CDKN1B PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; AGED; CHEMISTRY; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 63449140852     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2674     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007;205:231-8.
3. Kip1 deregulation in colorectal cancer. Cancer 2006;107: 668-75.
4. Kip1 chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1998;58:542-8.
5. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994;14:3683-94.
6. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
7. Loda M, Cukor B, Tam SW, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
8. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
9. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
10. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
11. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55:2266-9.
12. Kip1 in primary breast carcinomas. Hum Genet 1996;97:91-4.
13. Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745-51.
14. Shapira M, Ben-Izhak O, Bishara B, et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 2004;100:1615-21.
15. Palmquist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23.
16. Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes' B or proximal colorectal cancer. Int J Oncol 2001;19:49-52.
17. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103:1336-46.
18. Nalepa G, Harper JW. Therapeutic anti-cancer targets upstream of the proteosome. Cancer Treat Rev 2003;29:49-57.
19. Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23.
20. Thomas GV, Szigeti K, Murphy M, Draetta GF, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-7.
21. Hirano K, Minamoto T. Altered expression of p52 and p27 proteins, alone or combined, as a predictor of metastatic potential in early invasive carcinoma of the colon and rectum-a comparative clinicopathologic and molecular analysis. Cancer Detect Prevent 2000;24:343-55.
22. Saltz L, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-61.
23. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMLH1 and hMSH2 in tumours with microsatellite instabilityand genetic alterations in mismatch repair genes. Cancer Res 1996;56:4836-40.
24. Walsh S, Murphy M, Silverman M,et al. p27 expression in inflammatory bowel disease-associated neoplasia. J Pathol 1999;155:1511-8.
25. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leukovorin (IFL) in stage III colon cancer: CALGB protocol 89803. J Clin Oncol. In press 2008.
26. Kip1. Cancer Res 2007;67:10789-95.
27. Ogino S, Kawasaki T, Kirkner GJ,Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
28. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
29. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.